SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Anciotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice

Autores de INCLIVA

• Rebeca Ortega Herraiz

  Autor

• Aida Collado Sanchez

  Autor

• Francisca Sellés Sorlí

  Autor

• 

  Herminia González Navarro

  Autor

• 

  Maria Jesus Sanz Ferrando

  Autor

• 

  Jose Tomas Real Collado

  Autor

• 

  Laura Piqueras Ruiz

  Autor

Grupos y Plataformas de I+D+i

• Grupo de Investigación en Inflamación

  

  Leading Researcher

  Maria Jesus Sanz Ferrando

• Grupo de Investigación sobre Riesgo Cardiometabólico y Diabetes

  

  Leading Researcher

  Sergio Martinez Hervas

Abstract

OBJECTIVE: Abdominal aortic aneurysm (AAA) is a pathological condition of permanent vessel dilatation that predisposes to the potentially fatal consequence of aortic rupture. SGLT-2 (sodium-glucose cotransporter 2) inhibitors have emerged as powerful pharmacological tools for type 2 diabetes mellitus treatment. Beyond their glucose-lowering effects, recent studies have shown that SGLT-2 inhibitors reduce cardiovascular events and have beneficial effects on several vascular diseases such as atherosclerosis; however, the potential effects of SGLT-2 inhibition on AAA remain unknown. This study evaluates the effect of oral chronic treatment with empagliflozin-an SGLT-2 inhibitor-on dissecting AAA induced by Ang II (angiotensin II) infusion in apoE (apolipoprotein E)(-/-) mice. APPROACH AND RESULTS: Empagliflozin treatment significantly reduced the Ang II-induced increase in maximal suprarenal aortic diameter in apoE(-/-) mice independently of blood pressure effects. Immunohistochemistry analysis revealed that empagliflozin diminished Ang II-induced elastin degradation, neovessel formation, and macrophage infiltration at the AAA lesion. Furthermore, Ang II infusion resulted in a marked increase in the expression of chemokines (CCL-2 [chemokine (C-C motif) ligand 2] and CCL-5 [chemokine (C-C motif) ligand 5]), VEGF (vascular endothelial growth factor), and MMP (matrix metalloproteinase)-2 and MMP-9 in suprarenal aortic walls of apoE(-/-) mice, and all were reduced by empagliflozin cotreatment. Western blot analysis revealed that p38 MAPK (p38 mitogen-activated protein kinase) and NF-kappa B (nuclear factor-kappa B) activation was also reduced in the suprarenal aortas of apoE(-/-) mice cotreated with empagliflozin. Finally, in vitro studies in human aortic endothelial cells and macrophages showed that empagliflozin inhibited leukocyte-endothelial cell interactions and release of proinflammatory chemokines. CONCLUSIONS: Pharmacological inhibition of SGLT-2 by empagliflozin inhibits AAA formation. SGLT-2 inhibition might represent a novel promising therapeutic strategy to prevent AAA progression.

© 2019 American Heart Association, Inc

Keywords

• angiotensin II; animals; aortic aneurysm, abdominal; inflammation; sodium-glucose cotransporter type-2